|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2800 - 0.3050|
|52 Week Range||0.1000 - 0.6400|
|Beta (3Y Monthly)||-2.31|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2018 - Nov 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
· U.S. patent number US 10,053,376 entitled “Acoustic Pressure Shock Wave Devices and Methods for Fluids Processing” was issued on August 28, 2018 and has an effective life through December 2036. The patent includes twenty claims relating to the use of shockwaves for removing particulate matter from contaminated waters. · U.S. patent number US 10,058,340 entitled “Extracorporeal Pressure Shock Wave Devices with Multiple Reflectors and Methods for Using These Devices” was issued on August 28, 2018 and has an effective life through November 2032. The patent includes twenty claims relating to the use of extracorporeal shockwaves, generated from multiple reflectors for cardiovascular applications, orthopedic afflictions, infection elimination, and stem cells stimulation, proliferation and differentiation.
SUWANEE, GA, Dec. 07, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) SANUWAVE is excited to announce attendance at the 5th annual Innovations In Wound Healing.
SUWANEE, GA, Dec. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, announces the publication of the research that investigated the effects of dermaPACE® System (an Extracorporeal Shock Wave Technology (ESWT)) compared with Standard of Care in Diabetic Foot Ulcers (DFUs). The peer reviewed article, titled “Diabetic foot ulcer treatment with focused shockwave therapy: two multicentre prospective, controlled, double-blinded, randomised phase III clinical trials,” by Robert Snyder, DPM, Robert Galiano M.D., Perry Mayer MB, Oscar Alvarez PhD, Lee C. Rogers DPM, will be published in the December 2018 issue of the Journal of Wound Care.
Q3 Results, Operational Update: Robust Int’l Revenue, U.S. Should Benefit from Tracking Code…. SANUWAVE (SNWV) reported financial results and provided a business update (on two consecutive Q3 earnings calls). Revenue has now grown on a sequential basis for the fifth consecutive quarter and is trending at an annual run rate of more than $3M.
Total Revenue Increase of 269%;Initial US treatments have begun, New President, Shri Parikh, to Discuss on Conference Call at 10 am SUWANEE, Ga., Nov. 20, 2018 -- via.
SUWANEE, GA, Nov. 14, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) announced today that the Company will release financial results for the third quarter ended September 30, 2018 this week. The Company will also host a conference call on Thursday, November 15, 2018, beginning at 10AM Eastern Time to discuss the third quarter financial results, provide a business update and answer questions. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures.
SUWANEE, GA, Oct. 31, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave will exhibit at.
SUWANEE, GA , Oct. 17, 2018 -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company will exhibit at SAWC (Symposium on Advanced.
SUWANEE, GA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV) and Premier Shockwave, Inc. are pleased to announce that Premier Shockwave, Inc. and the dermaPACE® device were featured on American Indian Living Radio during the September 24, 2018 broadcast hosted by Dr. David DeRose. Dr. DeRose began the interview by saying that he had never heard of using shock waves to treat diabetic foot ulcers (DFUs) but had looked at some of the scientific photographs and found them to be “pretty impressive stuff.” Stolarski replied that the treatment was “very legitimate” and noted that the device was recently cleared by the FDA on December 28, 2017. Stolarski continued by detailing the 336-patient double-blinded, randomly-controlled FDA study conducted without physician assisted closure and without the assistance of antimicrobial or antibacterial assistance which achieved statistically significant rates of complete closure by 20 weeks in DFUs treated with dermaPACE® in conjunction with standard of care as compared to wounds treated with only standard of care.
Q2 Results, Operational Update: International Expansion Continues With 2 New JVs Signed in Q2…. Revenue continues to gain momentum, reflecting initial contribution from the recent U.S. launch and, to a greater degree, SNWV’s ever-expanding international footprint. Q2 revenue of $453k, which is the second-highest quarterly revenue in company history, was up more than 300% from the prior year and 32% from Q1 ’18.
Q1 ’18 marked a milestone for SNWV - or more accurately, marked three milestones. The $344k of revenue is the highest Q1 revenue in company history and it included U.S. dermaPACE revenue – which is another first. U.S. dermaPACE revenue relates to the first shipments to Premier Shockwave.